Alnylam Pharmaceuticals Re-elects Board Members and Approves Executive Compensation

Details

held its 2024 Annual Meeting of Stockholders. Stockholders re-elected four directors, approved the compensation of named executive officers in a non-binding vote, and ratified the appointment of PricewaterhouseCoopers LLP as the company's independent auditors for the fiscal year ending December 31, 2024.

Items reported

About Alnylam Pharmaceuticals Inc.

Alnylam Pharmaceuticals Inc. is a pioneering biotechnology company dedicated to transforming the lives of patients through RNA interference (RNAi) therapeutics. This scientific approach allows for innovative treatments that can silence genes responsible for certain diseases, offering a unique angle on genetic therapies. Alnylam's primary focus is on developing therapeutics for genetic, cardio-metabolic, hepatic infectious, and central nervous system diseases, contributing to redefining how these conditions are treated. The company's groundbreaking work in RNAi provides a platform for addressing otherwise untreatable or poorly managed medical conditions, positioning it as a leader in the biotechnology sector. With numerous collaborations, partnerships, and a growing pipeline of therapeutics, Alnylam plays a crucial role in advancing modern medicine and contributing to the evolving landscape of genetic therapeutics. Headquartered in Cambridge, Massachusetts, Alnylam underscores the critical intersection of innovation, medicine, and gene science in the financial and pharmaceutical markets.